Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
Although classical Hodgkin lymphoma (cHL) is usually curable, 20−30% of the patients experience treatment failure and most of them are typically treated with salvage chemotherapy and autologous stem cell transplantation (autoSCT). However, 45−55% of that subset further relapse or...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/8/1071 |